UNSPSC 51343111: Lopinavir

This classification denotes a protease inhibitor with the molecular formula C37H48N4O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2494G1JF75, chemically known as 1(2h)-pyrimidineacetamide, n-((1s,3s,4s)-4-(((2,6-dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahyrdo-alpha-1-methylethyl)-2-oxo-, (alphas)- but generally known as lopinavir, which bears US NIH Compound Identifier 92727.

UNSPSC 51343111 Lopinavir is a Commodity code for a specific antiretroviral pharmaceutical ingredient, yet recent state and local opportunities tagged under this code show little activity aligned with the code's nominal scope. The Illinois Department of Public Health awarded a completed pharmaceutical warehouse piggyback contract through MMCAP Infuse to Chartwell Rx LLC on August 28, 2026, but the award covered Doxycycline Hyclate and Ciprofloxacin Hydrochloride—antibiotics unrelated to Lopinavir. Seminole County, Florida posted a competitive bid for Naloxone and Safe Drug Deactivation Systems, a public health procurement equally unrelated to the code's antiretroviral focus. The mismatch between the code's stated scope and what is actually being solicited suggests that either the code assignment is inconsistent with how state and local procurement offices are tagging pharmaceutical purchases, or the code sees limited direct activity under its intended definition.

Recent activity centers on Florida and Illinois, though neither opportunity directly engages Lopinavir procurement. The Illinois award was a completed IFB with a 12-month initial term and renewal options, valued at $2,999,999.11 over the contract life, while Seminole County's IFB (posted June 30, 2026, due July 26, 2026) sought 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries. No set-aside designations or veteran business program requirements were noted in either record. The lack of Lopinavir-specific solicitations in recent state and local postings suggests the code is not actively used for this pharmaceutical category at the present time, or opportunities are being categorized under different codes despite the UNSPSC designation.